Ritter Pharmaceuticals Appoints CMO
This article was originally published in Scrip
Ritter Pharmaceuticals, Inc. has appointed AnnKatrin Petersen-Jappelli chief medical officer (CMO). Petersen-Jappelli, who is currently on the board of Salgomed Inc., brings 25 years of drug development experience to Ritter and was previously advisor, scientific research and clinical development leader of a Phase III program at Santarus Inc. Prior to this, she was vice-president of product development at MIGENIX Inc. and has held development positions at Pfizer, Sandoz (Novartis) and Agouron Pharmaceuticals.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.